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2. Hazard ratio estimate: Issues
2. f) No reference value
2.2) Wide condence intervals
2
2.3) Dependence of underlying study-specic censoring distributions


















2.4) Example- Cancer trial V- $f5-32$
6
Time (months) me (months)
reconstructed Iressa data.
3. Alternative model-free measures to the hazard ratio
3. f) Dierence (or ratio) of $t$-year survival probabilities
7
3.2) Dierence (or ratio) ofmedian survival times
events.
3.3) Dierence (or ratio) of restricted mean survival times
4. Secondary analysis of a non-inferiority study using the RMST
8
4. f) First method to determine RMST-based non inferiority margin
The $f\ovalbox{\tt\small REJECT} rst$ approach $\dot{\ovalbox{\tt\small REJECT}}s$ to use the $\dot{\ovalbox{\tt\small REJECT}}n\mathfrak{f}ormat\dot{\ovalbox{\tt\small REJECT}}on$ of the hazard $rat\dot{\ovalbox{\tt\small REJECT}}ow\dot{\ovalbox{\tt\small REJECT}}th$ the $foI|ow\dot{\ovalbox{\tt\small REJECT}}ng$ steps:
$\frac{h_{t}(t)}{h_{C}(t)}=\frac{m\cdot t^{m-1}}{\eta_{t^{m}}}/\frac{m\cdot t^{m-1}}{\eta_{c^{m}}}=\lambda$ , is satised, where $h_{t}(t)$ and $h_{c}(t)$ are the hazard functions
for the treatment group and the control group. From $th\dot{\ovalbox{\tt\small REJECT}}srelat\dot{\ovalbox{\tt\small REJECT}}onsh\dot{\ovalbox{\tt\small REJECT}}p,$ $\hat{\eta}_{t}$ can be
derived by $\hat{\eta}_{t}=\hat{\eta}_{c}/\exp(\frac{\log\lambda}{\hat{m}})$ .
4.2) Second method to determine RMST-based non-inferiority margin
9
4.3) Results
4.3. t) Summary of estimates
Estimate $($95% $C\ovalbox{\tt\small REJECT})$
12 months 24 months
ge tinib (months) 8.66 (8.16 to 9.16) 13.0 (11.9 to 14.1)
docetaxel (months) 9.53 (9.09 to 9.97) 14.1 (13.0 to 15.1)
Dierence (months)
$-0.9$ $(-1.5 to -0.2)$ $-1.1$ ($-2.6$ to 0.4)
(getinib minus docetaxel)
Ratio
0.91 (0.84 to 0.98) 0.92 (0.83 to 1.03)
(getinib over docetaxel)




4.3.2) Result of non inferiority by the rst method
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